Estrella Immunopharma Inc
estrellabio.comWhat Do They Do?
Develops T-cell therapies for patients with blood cancers, solid tumors, and autoimmune diseases.
10-K for FY2025, filed Mar 18, 2026We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and…View ↗
We are a clinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for…View ↗
We plan to expand our clinical investigation of our CD19-redirected ARTEMIS T-cell therapy into autoimmune diseases. Our EB201 program, in…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 18, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$2.3MView ↗
- ▼ −58% (Loss)
- vs −$5.5M in Q2 FY2025
-
Sep 1, 2026
Nasdaq notified the company of a market-value listing deficiency
The shares continue trading; the company has until March 1, 2027, to regain compliance.
Sources
8-K, filed Sep 8, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until…View ↗
-
Aug 21, 2026
Nasdaq notified the company of a minimum-bid-price listing deficiency
The stock continues trading; it has until February 16, 2027, to regain compliance.
Sources
8-K, filed Aug 21, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or…View ↗
From acquisition vehicle to drug developer
The older report describes TradeUP as a blank-check company seeking a business combination and Estrella as a prospective target; the latest report describes Estrella as a clinical-stage biopharmaceutical company developing T-cell therapies.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 18, 2026We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and…View ↗
Who Do They Compete With?
Competes with Novartis, Kite Pharma, Juno Therapeutics, JW Therapeutics, Allogene Therapeutics, Mustang Bio, Poseida Therapeutics, Autolus Therapeutics, Amgen, MorphoSys, and ADC Therapeutics
10-K for FY2025, filed Mar 18, 2026Novartis (Product: Kymriah)View ↗
Loading...
